Gemcitabine treatment can drive both upregulation of CD44 expression and CD44 isoform switching through insulin-like growth factor receptor 1 to confer gemcitabine resistance in PDA cells (49). The gene discussed is CD44; the disease is Patent ductus arteriosus.